Alzheimer’s antibody trial: is a new treatment in sight?

Written by Lauren Pulling

Researchers at the University of Zurich (UZH; Switzerland) have published findings from what could be a landmark clinical trial in the search for effective treatments for Alzheimer’s disease (AD). The new drug on trial, aducanumab, is an antibody that targets beta-amyloid plaques. The team demonstrated a significant reduction in plaques and a slowing in cognitive declined in AD patients treated with the drug, compared to a placebo control group. Aducanumab, a human monoclonal antibody, selectively binds amyloid plaques in the brain, enabling microglia to move between plaques. Following a year of treatment with the antibody as part of a Phase...

To view this content, please register now for access

It's completely free